TK2
Basic information
Region (hg38): 16:66508003-66552544
Links
Phenotypes
GenCC
Source:
- mitochondrial DNA depletion syndrome, myopathic form (Definitive), mode of inheritance: AR
- mitochondrial DNA depletion syndrome, myopathic form (Supportive), mode of inheritance: AR
- autosomal recessive progressive external ophthalmoplegia (Supportive), mode of inheritance: AR
- mitochondrial DNA depletion syndrome, myopathic form (Strong), mode of inheritance: AR
- mitochondrial disease (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Mitochondrial DNA depletion syndrome 2; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 3 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Biochemical; Musculoskeletal | 1734306; 11687801; 12391347; 18819985; 19125351; 19736010; 19815440; 20421844; 21937588; 22345218 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (30 variants)
- Mitochondrial DNA depletion syndrome, myopathic form (12 variants)
- Mitochondrial DNA depletion syndrome (4 variants)
- Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 3 (2 variants)
- Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 3;Mitochondrial DNA depletion syndrome, myopathic form (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TK2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 75 | 78 | ||||
missense | 12 | 14 | 93 | 126 | ||
nonsense | 11 | |||||
start loss | 2 | |||||
frameshift | 13 | 16 | ||||
inframe indel | 5 | |||||
splice donor/acceptor (+/-2bp) | 4 | |||||
splice region | 2 | 10 | 28 | 2 | 42 | |
non coding | 66 | 112 | 29 | 209 | ||
Total | 33 | 25 | 168 | 194 | 31 |
Highest pathogenic variant AF is 0.000158
Variants in TK2
This is a list of pathogenic ClinVar variants found in the TK2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-66508182-G-A | Mitochondrial DNA depletion syndrome, myopathic form | Benign (Jan 12, 2018) | ||
16-66508205-C-A | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 13, 2018) | ||
16-66508530-C-T | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 13, 2018) | ||
16-66508600-C-A | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Apr 27, 2017) | ||
16-66508637-G-A | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 12, 2018) | ||
16-66508683-C-T | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 12, 2018) | ||
16-66508713-T-C | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 13, 2018) | ||
16-66508750-T-G | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 12, 2018) | ||
16-66508775-C-T | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 12, 2018) | ||
16-66508983-C-T | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 13, 2018) | ||
16-66509024-C-A | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 13, 2018) | ||
16-66509054-G-A | Mitochondrial DNA depletion syndrome, myopathic form | Benign (Jan 13, 2018) | ||
16-66509066-G-A | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 12, 2018) | ||
16-66509195-G-C | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 13, 2018) | ||
16-66509331-C-T | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 13, 2018) | ||
16-66509428-C-A | Mitochondrial DNA depletion syndrome, myopathic form | Likely benign (Jan 13, 2018) | ||
16-66509518-T-C | Mitochondrial DNA depletion syndrome, myopathic form | Benign (Jan 13, 2018) | ||
16-66509535-T-C | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 13, 2018) | ||
16-66509549-G-A | Mitochondrial DNA depletion syndrome, myopathic form | Benign (Jan 12, 2018) | ||
16-66509593-C-T | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 13, 2018) | ||
16-66509670-G-A | Mitochondrial DNA depletion syndrome, myopathic form | Likely benign (Jan 12, 2018) | ||
16-66509747-A-G | Mitochondrial DNA depletion syndrome, myopathic form | Benign (Jan 13, 2018) | ||
16-66509822-C-T | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 13, 2018) | ||
16-66509846-C-T | Mitochondrial DNA depletion syndrome | Uncertain significance (Jun 14, 2016) | ||
16-66509847-G-A | Mitochondrial DNA depletion syndrome, myopathic form | Uncertain significance (Jan 12, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TK2 | protein_coding | protein_coding | ENST00000451102 | 10 | 44542 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.91e-7 | 0.596 | 125719 | 0 | 29 | 125748 | 0.000115 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.153 | 139 | 144 | 0.964 | 0.00000860 | 1716 |
Missense in Polyphen | 45 | 54.178 | 0.83059 | 652 | ||
Synonymous | -0.890 | 64 | 55.6 | 1.15 | 0.00000366 | 490 |
Loss of Function | 1.01 | 12 | 16.4 | 0.732 | 7.24e-7 | 202 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000210 | 0.000210 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.000132 | 0.000132 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.000261 | 0.000261 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Phosphorylates thymidine, deoxycytidine, and deoxyuridine in the mitochondrial matrix. In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on TK2 and DGUOK. Widely used as target of antiviral and chemotherapeutic agents. {ECO:0000269|PubMed:11687801}.;
- Disease
- DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 3 (PEOB3) [MIM:617069]: A form of progressive external ophthalmoplegia, a mitochondrial myopathy characterized by progressive paralysis of the levator palpebrae, orbicularis oculi, and extraocular muscles. PEOB3 patients manifest adult-onset progressive external ophthalmoplegia and progressive proximal muscle weakness associated with muscle atrophy. {ECO:0000269|PubMed:21937588}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Pyrimidine metabolism - Homo sapiens (human);Drug metabolism - other enzymes - Homo sapiens (human);Pyrimidine metabolism;Metabolism of nucleotides;Metabolism;Pyrimidine salvage;Nucleotide salvage;Pyrimidine metabolism;superpathway of pyrimidine deoxyribonucleoside salvage;Pyrimidine nucleotides nucleosides metabolism;pyrimidine deoxyribonucleosides salvage
(Consensus)
Recessive Scores
- pRec
- 0.649
Intolerance Scores
- loftool
- 0.139
- rvis_EVS
- -0.25
- rvis_percentile_EVS
- 35.42
Haploinsufficiency Scores
- pHI
- 0.179
- hipred
- N
- hipred_score
- 0.208
- ghis
- 0.558
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.574
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tk2
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan);
Gene ontology
- Biological process
- nucleobase-containing compound metabolic process;deoxyribonucleoside monophosphate biosynthetic process;nucleotide biosynthetic process;phosphorylation;pyrimidine nucleoside salvage;deoxycytidine metabolic process;thymidine metabolic process;DNA biosynthetic process
- Cellular component
- cytoplasm;mitochondrion;mitochondrial matrix
- Molecular function
- deoxycytidine kinase activity;thymidine kinase activity;ATP binding;deoxynucleoside kinase activity;nucleoside kinase activity